BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Qu CY, Zheng Y, Zhou M, Zhang Y, Shen F, Cao J, Xu LM. Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. World J Gastroenterol 2015; 21(16): 5072-5080 [PMID: 25945023 DOI: 10.3748/wjg.v21.i16.5072]
URL: https://www.wjgnet.com/1007-9327/full/v21/i16/5072.htm
Number Citing Articles
1
Álvaro Esteban Alfaro Alfaro, Brayan Murillo Castillo, Eugenia Cordero García, Javier Tascón, Ana I. Morales. Colon Cancer Pharmacogenetics: A Narrative ReviewPharmacy 2022; 10(4): 95 doi: 10.3390/pharmacy10040095
2
Nuttavut Sumransub, Kornpong Vantanasiri, Ajay Prakash, Emil Lou. Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?Molecular Therapy - Oncolytics 2021; 22: 1 doi: 10.1016/j.omto.2021.05.001
3
Edina Tolnay, �ron Ghimessy, Erzs�bet Juh�sz, Zsuzsanna Sztancsik, Gy�rgy Losonczy, P�ter Dombi, Zsuzsanna Vennes, L�szl� Helf, Edit Csada, Veronika S�rosi. The efficacy and safety of bevacizumab in addition to platinum‑based chemotherapy for the first‑line treatment of patients with advanced nonsquamous non‑small‑cell lung cancer: Final results of AVALANCHE, an observational cohort studyOncology Letters 2018;  doi: 10.3892/ol.2018.9766
4
Jia Deng, Xinglin Zeng, Wenting Hu, Tinghui Yue, Zicheng Luo, Lian Zeng, Ping Li, Jiang Chen. Different doses of bevacizumab in combination with chemotherapy for advanced colorectal cancer: a meta-analysis and Bayesian analysisInternational Journal of Colorectal Disease 2023; 38(1) doi: 10.1007/s00384-023-04442-5
5
Usman Ilyas, Zaryab Umar, Amee M Pansuriya, Abrahim Mahmood, Muhammad Haseeb ul Rasool, Zamaraq Bhatti. Rare Mucinous Adenocarcinoma of the Appendix Undergoing Multiple Recurrent Surgical InterventionsCureus 2023;  doi: 10.7759/cureus.33294
6
Selma YAMAN, Nursima ÇUKADAR, Furkan BARAN, Fatih Burak UYANIK, Metin KILINÇ, Tufan MERT. Monoklonal antikorlardan bevacizumab'ın deneysel inflamatuar ağrı modelinde antianjiyogenik etkisiCukurova Medical Journal 2019; 44: 33 doi: 10.17826/cumj.532813
7
Masahito Naito, Ryota Torii, Yuki Hashimoto, Yuki Kawamoto, Kenichi Hayashi, Hiroaki Shinoda, Yumiko Honjo, Motoki Hiroyoshi. Increase in Carbohydrate Antigen 19-9 Levels without Tumor Progression after Polaprezinc Administration that Induced Deep Vein Thrombosis in a Colon Cancer PatientChemotherapy 2019; 64(3): 163 doi: 10.1159/000503221
8
Elena M. Tosca, Maurizio Rocchetti, Enrico Pesenti, Paolo Magni. A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab ResistanceCancer Research 2020; 80(4): 820 doi: 10.1158/0008-5472.CAN-19-0811
9
F.I. Mulder, N. van Es, N. Kraaijpoel, M. Di Nisio, M. Carrier, A. Duggal, M. Gaddh, D. Garcia, M.A. Grosso, A.K. Kakkar, M.F. Mercuri, S. Middeldorp, G. Royle, A. Segers, S. Shivakumar, P. Verhamme, T. Wang, J.I. Weitz, G. Zhang, H.R. Büller, G. Raskob. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer studyThrombosis Research 2020; 185: 13 doi: 10.1016/j.thromres.2019.11.007
10
Tijl Vermassen, Karen Geboes, Marc De Man, Stéphanie Laurent, Elsie Decoene, Nicolaas Lumen, Joris Delanghe, Sylvie Rottey. Neither creatinine- nor cystatin C-estimated glomerular filtration rate is optimal in oncology patients treated with targeted agentsNephrology Dialysis Transplantation 2018; 33(3): 402 doi: 10.1093/ndt/gfx063
11
Erdem Bangi, Celina Ang, Peter Smibert, Andrew V. Uzilov, Alexander G. Teague, Yevgeniy Antipin, Rong Chen, Chana Hecht, Nelson Gruszczynski, Wesley J. Yon, Denis Malyshev, Denise Laspina, Isaiah Selkridge, Hope Rainey, Aye S. Moe, Chun Yee Lau, Patricia Taik, Eric Wilck, Aarti Bhardwaj, Max Sung, Sara Kim, Kendra Yum, Robert Sebra, Michael Donovan, Krzysztof Misiukiewicz, Eric E. Schadt, Marshall R. Posner, Ross L. Cagan. A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancerScience Advances 2019; 5(5) doi: 10.1126/sciadv.aav6528
12
Yuta Hara, Ryota Torii, Shiho Ueda, Erina Kurimoto, Eri Ueda, Hiroshi Okura, Yutaka Tatano, Hideki Yagi, Yoshiya Ohno, Toshiyuki Tanaka, Kazue Masuko, Takashi Masuko. Inhibition of tumor formation and metastasis by a monoclonal antibody against lymphatic vessel endothelial hyaluronan receptor 1Cancer Science 2018; 109(10): 3171 doi: 10.1111/cas.13755
13
Jae Hyun Kim, Seun Ja Park. Target Therapy in Unresectable or Metastatic Colorectal CancerThe Korean Journal of Gastroenterology 2016; 68(6): 303 doi: 10.4166/kjg.2016.68.6.303
14
Hakan Kulacoglu, Ferdinand Köckerling. Hernia and Cancer: The Points Where the Roads IntersectFrontiers in Surgery 2019; 6 doi: 10.3389/fsurg.2019.00019
15
Diana Cornelia Moisuc, Mihai Vasile Marinca, Bogdan Gafton, Teodora Alexa-Stratulat, Mariana Pavel-Tanasa, Petru Cianga. Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal CancerCurrent Oncology 2022; 29(6): 3996 doi: 10.3390/curroncol29060319
16
Naoya Toriu, Akinari Sekine, Hiroki Mizuno, Eiko Hasegawa, Masayuki Yamanouchi, Rikako Hiramatsu, Noriko Hayami, Junichi Hoshino, Masahiro Kawada, Tatsuya Suwabe, Keiichi Sumida, Naoki Sawa, Kenmei Takaichi, Kenichi Ohashi, Takeshi Fujii, Shuichiro Matoba, Yoshifumi Ubara. Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case ReportCase Reports in Oncology 2019; 12(2): 391 doi: 10.1159/000500716
17
Prashanth Rawla, Adam Barsouk, Andreas V. Hadjinicolaou, Alexander Barsouk. Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal CancerMedical Sciences 2019; 7(8): 83 doi: 10.3390/medsci7080083
18
Li Ai, Chen Xin, Muhammad Usman, Yu Zhu, Hong Lu. Effect of Bevacizumab on traumatic penumbra brain edema in rats at different time pointsTissue Barriers 2023;  doi: 10.1080/21688370.2023.2292463
19
Philip Emmerich, Linda Clipson, Dustin A. Deming. Resistance Mechanisms to Colorectal Cancer Therapeutics and the Clinical ImplicationsCurrent Colorectal Cancer Reports 2017; 13(4): 334 doi: 10.1007/s11888-017-0374-5
20
Helga Hagman, Pär-Ola Bendahl, Jon Lidfeldt, Mattias Belting, Anders Johnsson, Aamir Ahmad. Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancerPLOS ONE 2018; 13(12): e0209838 doi: 10.1371/journal.pone.0209838
21
Minjie Fu, Zhirui Zhou, Xiao Huang, Zhenchao Chen, Licheng Zhang, Jinsen Zhang, Wei Hua, Ying Mao. Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence mapBMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-11043-6
22
Minjie Fu, Arshad Hussain, Youting Dong, Yang Fei. A retrospective analysis of GSE84010: Cell adhesion molecules might contribute to bevacizumab resistance in glioblastomaJournal of Clinical Neuroscience 2021; 86: 110 doi: 10.1016/j.jocn.2021.01.019
23
Tobias Engel Ayer Botrel, Luciana Gontijo de Oliveira Clark, Luciano Paladini, Otávio Augusto C. Clark. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysisBMC Cancer 2016; 16(1) doi: 10.1186/s12885-016-2734-y
24
Chinese consensus on prevention of colorectal neoplasia (2021, Shanghai)Journal of Digestive Diseases 2022; 23(2): 58 doi: 10.1111/1751-2980.13079
25
N.A. Bhaskaran, L. Kumar. Treating colon cancers with a non-conventional yet strategic approach: An overview of various nanoparticulate systemsJournal of Controlled Release 2021; 336: 16 doi: 10.1016/j.jconrel.2021.06.008
26
Dengfeng Wang, Yang Yu, Pengxian Tao, Dan Wang, Yajing Chen, Hao Chen. Risk of venous thromboembolism in patients undergoing gastric cancer surgery: protocol for a systematic review and meta-analysisBMJ Open 2020; 10(1): e033267 doi: 10.1136/bmjopen-2019-033267
27
Susan A. Kennedy, Maria E. Morrissey, Margaret R. Dunne, Fiona O’Connell, Clare T. Butler, Mary-Clare Cathcart, Amy M. Buckley, Brian J. Mehigan, John O. Larkin, Paul McCormick, Breandán N. Kennedy, Jacintha O’Sullivan. Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumorsBMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07430-y
28
Pasquale F. Innominato, René Adam. Use of Bevacizumab in the Management of Potentially Resectable Colorectal Liver Metastases: Safety, Pathologic Assessment and BenefitCurrent Colorectal Cancer Reports 2016; 12(4): 208 doi: 10.1007/s11888-016-0326-5
29
Hasan Ahmad Albitar, Yahya Almodallal, Rick Nishimura, Vivek N. Iyer. Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous BevacizumabMayo Clinic Proceedings: Innovations, Quality & Outcomes 2020; 4(4): 460 doi: 10.1016/j.mayocpiqo.2020.01.002
30
Alok K. Mishra. Phagocytosis - Main Key of Immune SystemPhysiology 2023; 19 doi: 10.5772/intechopen.110619
31
Zipeng Lu, Maximilian Weniger, Kuirong Jiang, Stefan Boeck, Kai Zhang, Alexander Bazhin, Yi Miao, Jens Werner, Jan G. D’Haese. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-AnalysisTargeted Oncology 2018; 13(4): 447 doi: 10.1007/s11523-018-0578-x
32
Sabina Palma, Ariel O. Zwenger, María V. Croce, Martín C. Abba, Ezequiel Lacunza. From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer TherapyClinical Colorectal Cancer 2016; 15(2): 104 doi: 10.1016/j.clcc.2015.11.001
33
M. Di Nisio, M. Candeloro, A.W.S. Rutjes, E. Porreca. Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis 2018; 16(7): 1336 doi: 10.1111/jth.14149
34
Alexander Baraniskin, Barbara Buchberger, Christian Pox, Ulli Graeven, Julian W. Holch, Wolff Schmiegel, Volker Heinemann. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysisEuropean Journal of Cancer 2019; 106: 37 doi: 10.1016/j.ejca.2018.10.009
35
Minsu Lee, Jin-Young Choi, Joon Seok Lim, Mi-Suk Park, Myeong-Jin Kim, Honsoul Kim. Lack of anti-tumor activity by anti-VEGF treatments in hepatic hemangiomasAngiogenesis 2016; 19(2): 147 doi: 10.1007/s10456-016-9494-9
36
Matthieu Siebert, Mohammad Alyami, Frederic Mercier, Colin Gallice, Laurent Villeneuve, Nathalie Laplace, Guillaume Passot, Naoual Bakrin, Olivier Glehen, Vahan Kepenekian. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. A single center comparative studyEuropean Journal of Surgical Oncology 2021; 47(1): 139 doi: 10.1016/j.ejso.2019.03.021
37
Jinhai Huang, Wenwen Wang, Jing Yu, Xinxin Yu, Qianqian Zheng, Fangli Peng, Zhifen He, Wenguang Zhao, Zhaoliang Zhang, Xingyi Li, Qinmei Wang. Combination of dexamethasone and Avastin® by supramolecular hydrogel attenuates the inflammatory corneal neovascularization in rat alkali burn modelColloids and Surfaces B: Biointerfaces 2017; 159: 241 doi: 10.1016/j.colsurfb.2017.07.057
38
Wanjing Feng, Xiaodong Zhu. Efficacy prediction of targeted therapy for gastric cancer: The current status (Review)Molecular Medicine Reports 2018;  doi: 10.3892/mmr.2018.9145
39
Ikhwan Rinaldi, Kevin Winston, Leroy David Vincent, Abdillah Wicaksono, Muhammad Prasetio Wardoyo, Yusuf Aji Samudera Nurrobi, Jessica Leoni. Overall Survival and Progression-Free Survival Comparison of Bevacizumab Plus Chemotherapy Combination Regiment versus Chemotherapy Only Regiment in Previously Untreated Metastatic Colorectal Cancer: Systematic Review and Meta-AnalysisOpen Access Macedonian Journal of Medical Sciences 2022; 10(F): 269 doi: 10.3889/oamjms.2022.9375
40
Lidia Rita Corsini, Daniele Fanale, Francesco Passiglia, Lorena Incorvaia, Vincenzo Gennusa, Viviana Bazan, Antonio Russo. Monoclonal antibodies for the treatment of non-hematological tumors: a safety reviewExpert Opinion on Drug Safety 2018; 17(12): 1197 doi: 10.1080/14740338.2018.1550068
41
Cindy Neuzillet, Benoît Rousseau, Hemant Kocher, Philippe Bourget, Christophe Tournigand. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomasPharmacology & Therapeutics 2017; 174: 145 doi: 10.1016/j.pharmthera.2017.02.028
42
Grigoris T. Gerotziafas, Ismail Elalamy. Risque thromboembolique en oncologie : réalités, actualités et perspectivesBulletin du Cancer 2016; 103(9): 764 doi: 10.1016/j.bulcan.2016.07.001
43
Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Linda Farkas, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, Lisa A. Gurski. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network 2021; 19(3): 329 doi: 10.6004/jnccn.2021.0012
44
Lee S. Rosen, Ira A. Jacobs, Ronald L. Burkes. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of BiosimilarsTargeted Oncology 2017; 12(5): 599 doi: 10.1007/s11523-017-0518-1
45
Courtney S. Malo, Roman H. Khadka, Katayoun Ayasoufi, Fang Jin, Jackson E. AbouChehade, Michael J. Hansen, Raymond Iezzi, Kevin D. Pavelko, Aaron J. Johnson. Immunomodulation Mediated by Anti-angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental GliomaFrontiers in Oncology 2018; 8 doi: 10.3389/fonc.2018.00320
46
Giandomenico Roviello, Chiara Pacifico, Paola Corona, Daniele Generali. Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysisInvestigational New Drugs 2017; 35(4): 518 doi: 10.1007/s10637-017-0452-1
47
Christina E. Bailey, Alexander A. Parikh. Assessment of the risk of antiangiogenic agents before and after surgeryCancer Treatment Reviews 2018; 68: 38 doi: 10.1016/j.ctrv.2018.05.002
48
Jorge Pablo Grondona. Extreme Hepatic Surgery and Other Strategies2017; : 79 doi: 10.1007/978-3-319-13896-1_6
49
David Arias Ron, Carmen M. Labandeira, Soledad Cameselle García, Jesús García Mata, Mercedes Salgado Fernández. Sustained Stable Disease with Capecitabine plus Bevacizumab in Metastatic Appendiceal Adenocarcinoma: A Case ReportCase Reports in Oncology 2020; 13(1): 69 doi: 10.1159/000505237
50
Marco Ravanelli, Giorgio Maria Agazzi, Elena Tononcelli, Elisa Roca, Paolo Cabassa, Gianluca Baiocchi, Alfredo Berruti, Roberto Maroldi, Davide Farina. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapyLa radiologia medica 2019; 124(9): 877 doi: 10.1007/s11547-019-01046-4
51
Luisa Seguella, Riccardo Capuano, Mirella Pesce, Giuseppe Annunziata, Marcella Pesce, Barbara de Conno, Giovanni Sarnelli, Laura Aurino, Giuseppe Esposito. S100B Protein Stimulates Proliferation and Angiogenic Mediators Release through RAGE/pAkt/mTOR Pathway in Human Colon Adenocarcinoma Caco-2 CellsInternational Journal of Molecular Sciences 2019; 20(13): 3240 doi: 10.3390/ijms20133240
52
Marina T Van Leeuwen, Steven Luu, Howard Gurney, Martin R Brown, Sallie-Anne Pearson, Kate Webber, Lee Hunt, Soojung Hong, Geoffrey P Delaney, Claire M Vajdic. Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic ReviewsJNCI Cancer Spectrum 2020; 4(6) doi: 10.1093/jncics/pkaa076